Fulgent Genetics 미래 성장

Future 기준 확인 1/6

Fulgent Genetics 의 수익은 연간 9.7% 감소할 것으로 예상되는 반면, 연간 수익은 8.9% 로 증가할 것으로 예상됩니다. 8.9% 연간. EPS는 연간 18.1% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -1.2% 로 예상됩니다.

주요 정보

-9.7%

수익 성장률

-18.1%

EPS 성장률

Healthcare 수익 성장	17.4%
매출 성장률	8.9%
향후 자기자본 수익률	-1.2%
애널리스트 커버리지	Low
마지막 업데이트	04 Mar 2025

최근 미래 성장 업데이트

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07

Recent updates

Laboratory, Pathology And Therapeutics Will Expand Future Capabilities

Mar 28 Fulgent Genetics' laboratory services success and sales team's efficiency improvements should drive revenue growth and improve gross margins.

Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

Mar 20

Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Jul 17

Fulgent Genetics: Growth Is Returning

Jun 06

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

수익 및 매출 성장 예측

NasdaqGM:FLGT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	370	-57	N/A	N/A	2
12/31/2026	341	-60	N/A	N/A	3
12/31/2025	310	-60	N/A	N/A	3
12/31/2024	283	-43	-19	21	N/A
9/30/2024	278	-165	-29	11	N/A
6/30/2024	291	-163	12	37	N/A
3/31/2024	288	-166	18	42	N/A
12/31/2023	289	-168	5	27	N/A
9/30/2023	286	-64	21	45	N/A
6/30/2023	307	-49	31	56	N/A
3/31/2023	365	-26	42	57	N/A
12/31/2022	619	143	235	254	N/A
9/30/2022	803	272	277	297	N/A
6/30/2022	925	392	411	429	N/A
3/31/2022	953	461	476	494	N/A
12/31/2021	993	507	515	539	N/A
9/30/2021	1,036	569	554	596	N/A
6/30/2021	910	493	405	453	N/A
3/31/2021	773	417	327	372	N/A
12/31/2020	422	214	105	141	N/A
9/30/2020	135	48	-6	6	N/A
6/30/2020	44	3	-1	1	N/A
3/31/2020	35	0	4	6	N/A
12/31/2019	33	0	4	6	N/A
9/30/2019	30	-2	6	6	N/A
6/30/2019	25	-4	1	2	N/A
3/31/2019	22	-6	0	2	N/A
12/31/2018	21	-6	-4	-1	N/A
9/30/2018	20	-5	N/A	-3	N/A
6/30/2018	19	-6	N/A	-2	N/A
3/31/2018	18	-5	N/A	-1	N/A
12/31/2017	19	-3	N/A	1	N/A
9/30/2017	20	0	N/A	4	N/A
6/30/2017	21	-5	N/A	4	N/A
3/31/2017	20	-13	N/A	5	N/A
12/31/2016	18	-14	N/A	4	N/A
9/30/2016	15	-22	N/A	3	N/A
6/30/2016	13	-15	N/A	2	N/A
3/31/2016	11	-6	N/A	0	N/A
12/31/2015	10	-5	N/A	-1	N/A
12/31/2014	1	-1	N/A	-4	N/A

애널리스트 미래 성장 예측

수입 대 저축률: FLGT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: FLGT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: FLGT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: FLGT 의 수익(연간 8.9% ) US 시장( 8.3% 보다 빠르게 성장할 것으로 예상됩니다. 8.3% 연간).

고성장 수익: FLGT 의 수익(연간 8.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: FLGT (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/04/14 10:18
장 마감 주가	2025/04/11 00:00
수익	2024/12/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Fulgent Genetics, Inc. 6 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Karen Koski	BTIG
Andrew Cooper	CGS International
Erin Wilson Wright	Credit Suisse

Fulgent Genetics 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Fulgent Genetics, Inc. Provides Earnings Guidance for the Full Year 2025

Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Recent updates

Fulgent Genetics, Inc. to Report Q1, 2025 Results on May 02, 2025

Laboratory, Pathology And Therapeutics Will Expand Future Capabilities

Fulgent Genetics, Inc., Annual General Meeting, May 15, 2025

Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

Fulgent Genetics, Inc. Provides Earnings Guidance for the Full Year 2025

Fulgent Genetics, Inc. to Report Q4, 2024 Results on Feb 28, 2025

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Fulgent Genetics: A Value Stock With Caveats (Rating Downgrade)

Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio

Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024

Fulgent Genetics: Growth Is Returning

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

COO & President recently sold US$583k worth of stock

COO & President notifies of intention to sell stock

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Price target decreased by 14% to US$36.50

Chief Financial Officer recently sold US$346k worth of stock

Chief Financial Officer notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

COO & President notifies of intention to sell stock

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Price target decreased by 7.4% to US$41.67

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Chief Financial Officer recently sold US$23k worth of stock

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold US$64k worth of stock

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Less than half of directors are independent

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Wait For Fulgent Genetics To Grow Up

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc